BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24687367)

  • 1. Clinical usefulness of the PAXgene™ bone marrow RNA system for stabilizing total RNA.
    Takeda M; Funato T; Ikemoto M; Nanmoku T; Urasaki Y; Iwatani Y
    J Clin Lab Anal; 2015 Jan; 29(1):61-7. PubMed ID: 24687367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examination of stability of bone marrow blood RNA in the PAXgene tube.
    Yamamoto T; Sekiyama A; Sekiguchi H; Yoshida T; Miyagi Y
    Lab Hematol; 2006; 12(3):143-7. PubMed ID: 16950675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study.
    Willasch AM; Gruhn B; Coliva T; Kalinova M; Schneider G; Kreyenberg H; Steinbach D; Weber G; Hollink IH; Zwaan CM; Biondi A; van der Velden VH; Reinhardt D; Cazzaniga G; Bader P; Trka J;
    Leukemia; 2009 Aug; 23(8):1472-9. PubMed ID: 19322206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood.
    Kitamura K; Nishiyama T; Ishiyama K; Miyawaki S; Miyazaki K; Suzuki K; Masaie H; Okada M; Ogawa H; Imai K; Kiyoi H; Naoe T; Yokoyama Y; Chiba S; Hata T; Miyazaki Y; Hatta Y; Takeuchi J; Nannya Y; Kurokawa M; Ueda Y; Koga D; Sugiyama H; Takaku F
    Int J Hematol; 2016 Jan; 103(1):53-62. PubMed ID: 26520650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation.
    Zhong L; Wei L; Chen J; Huang X; Gong Y; Lu Y
    Mol Diagn Ther; 2015 Aug; 19(4):205-12. PubMed ID: 26138637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of WT1 and PRAME gene in bone marrow and peripheral blood samples of patients with myelodysplastic syndrome].
    Lu D; Qin YZ; Li LD; Shi HX; Lai YY; Liu YR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):370-6. PubMed ID: 24763007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Detection of WT1 expression in bone marrow of acute leukemia patients with real-time quantitative RT-PCR].
    Gu WY; Chen ZX; Cao XS; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J
    Zhonghua Xue Ye Xue Za Zhi; 2004 Dec; 25(12):728-31. PubMed ID: 15730716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells.
    Hosen N; Sonoda Y; Oji Y; Kimura T; Minamiguchi H; Tamaki H; Kawakami M; Asada M; Kanato K; Motomura M; Murakami M; Fujioka T; Masuda T; Kim EH; Tsuboi A; Oka Y; Soma T; Ogawa H; Sugiyama H
    Br J Haematol; 2002 Feb; 116(2):409-20. PubMed ID: 11841446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia.
    Garg M; Moore H; Tobal K; Liu Yin JA
    Br J Haematol; 2003 Oct; 123(1):49-59. PubMed ID: 14510942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels.
    Inoue K; Ogawa H; Yamagami T; Soma T; Tani Y; Tatekawa T; Oji Y; Tamaki H; Kyo T; Dohy H; Hiraoka A; Masaoka T; Kishimoto T; Sugiyama H
    Blood; 1996 Sep; 88(6):2267-78. PubMed ID: 8822948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia.
    Jurlander J; Caligiuri MA; Ruutu T; Baer MR; Strout MP; Oberkircher AR; Hoffmann L; Ball ED; Frei-Lahr DA; Christiansen NP; Block AM; Knuutila S; Herzig GP; Bloomfield CD
    Blood; 1996 Sep; 88(6):2183-91. PubMed ID: 8822938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.
    Cilloni D; Gottardi E; Messa F; Fava M; Scaravaglio P; Bertini M; Girotto M; Marinone C; Ferrero D; Gallamini A; Levis A; Saglio G;
    J Clin Oncol; 2003 May; 21(10):1988-95. PubMed ID: 12743153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.
    Cilloni D; Messa F; Gottardi E; Fava M; Arruga F; Defilippi I; Carturan S; Messa E; Morotti A; Giugliano E; Rege-Cambrin G; Alberti D; Baccarani M; Saglio G
    Cancer; 2004 Sep; 101(5):979-88. PubMed ID: 15329907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome.
    Bergmann L; Miething C; Maurer U; Brieger J; Karakas T; Weidmann E; Hoelzer D
    Blood; 1997 Aug; 90(3):1217-25. PubMed ID: 9242555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
    Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
    Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child-specific reference values.
    Løvvik Juul-Dam K; Guldborg Nyvold C; Vålerhaugen H; Zeller B; Lausen B; Hasle H; Beier Ommen H
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27671. PubMed ID: 30900388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of gene-expression profiles in parallel bone marrow and peripheral blood samples in acute myeloid leukaemia by real-time polymerase chain reaction.
    Sakhinia E; Farahangpour M; Tholouli E; Liu Yin JA; Hoyland JA; Byers RJ
    J Clin Pathol; 2006 Oct; 59(10):1059-65. PubMed ID: 16644881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study.
    Østergaard M; Olesen LH; Hasle H; Kjeldsen E; Hokland P
    Br J Haematol; 2004 Jun; 125(5):590-600. PubMed ID: 15147374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia.
    Weisser M; Kern W; Rauhut S; Schoch C; Hiddemann W; Haferlach T; Schnittger S
    Leukemia; 2005 Aug; 19(8):1416-23. PubMed ID: 15920493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia.
    Shabani M; Asgarian-Omran H; Vossough P; Sharifian RA; Faranoush M; Ghragozlou S; Khoshnoodi J; Roohi A; Jeddi-Tehrani M; Mellstedt H; Rabbani H; Shokri F
    Leuk Lymphoma; 2008 Jul; 49(7):1360-7. PubMed ID: 18604725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.